First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCLPazos Manuel,Brian Estrella,Ted B. Piorczynski,Seda S. Tolu, Wenxuan Huang,Yun Kyoung Ryu,Jennifer E AmengualBlood(2023)引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要